Study examines benefits of SGLT2 inhibitors in people with type 1 diabetes
In addition to lowering blood sugar levels, diabetes medicines called sodium-glucose cotransporter 2 (SGLT2) inhibitors may provide kidney and cardiovascular benefits in people with type 2 diabetes. A recent study looked at whether such benefits are also felt by people with type 1 diabetes. The results will be presented online during ASN Kidney Week 2021 from November 4-7.
The study applied Steno type 1 risk drivers, validated prediction models for cardiovascular disease and kidney failure in people with type 1 diabetes, to 3,660 adults with type 1 diabetes who have treated from 2001 to 2016. The use of SGLT2 inhibitors was linked to a 6.1% lower risk of cardiovascular disease over 5 years (with an up to 11.1% lower risk in people with signs kidney disease) and with a 5.3% lower risk of kidney failure (up to 7.6% lower risk in people with signs of kidney disease).
In our study, we showed significant reductions in the risk of cardiovascular disease and renal failure with SGLT2 inhibitor treatment in type 1 diabetes. Our model provides an estimate of benefit that may balance the risks associated with the use of SGLT2 inhibitors in type 1 diabetes. “
Elisabeth Stougaard, PhD, lead author, Steno Diabetes Center, Copenhagen
Study: “Sodium-glucose co-transporter 2 inhibitors as an adjunct treatment for type 1 diabetes and the benefit on cardiovascular and renal diseases evaluated by the Steno risk drivers”
American Society of Nephrology